- Barrons.com•8 hours ago
RBC's Simos Simeonidis and Matthew Eckler try to find the right comparison for Pfizer's (PFE) purchase of Medivation (MDVN): We were obviously wrong with our Sector Perform rating: while we knew an M&A transaction was definitely a good possibility, we just could not get to this level of valuation using a realistic Xtandi model and thus could not recommend the stock.
- Barrons.com•13 hours ago
Yesterday, we highlighted six stocks that the folks at Citigroup contend could be buyout targets following Pfizer's (PFE) $14 billion purchase of Medivation (MDVN). Today, Gabelli's Jing He offers four ...
Gilead Sciences Inc. (GILD)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||81.47 x 100|
|Ask||81.64 x 200|
|Day's Range||81.02 - 81.64|
|52wk Range||77.92 - 113.31|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||7.15|
|Avg Vol (3m)||10,168,300|
|Dividend & Yield||1.88 (2.32%)|